Dr. Jun Zhu 朱军
Chief Physician
Department of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and combined radiotherapy and chemotherapy for esophageal, lung, breast, and rectal cancers. Management of radiotherapy complications and sequelae.
Dr. Zhu is a Chief Physician and master’s supervisor at Nanjing Medical University. Expertise includes precision radiotherapy, stereotactic radiotherapy, and managing treatment side effects. Dr. Zhu has published over 40 papers, including 16 indexed in SCI. Dr. Zhu led or participated in multiple provincial research projects and received provincial awards for new technology introduction.
Name order: in Chinese the family name comes first (Zhu Jun). Papers usually list the name as Jun Zhu or Zhu J.
Selected publications
55 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Br J Haematol, 2025 (senior author): Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study. PubMed 40888120
- Lancet Oncol, 2024 (senior author): Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. PubMed 38092009
- Cytotherapy, 2023 (senior author): Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study. PubMed 36842849
- Am J Hematol, 2022 (senior author): Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial. PubMed 36053875
- Int J Cancer, 2022 (senior author): Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study. PubMed 34674396
- Expert Rev Hematol, 2021 (senior author): Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma. PubMed 34275403
- Cancer Med, 2021 (senior author): Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. PubMed 33382529
- Cancer Med, 2020 (senior author): Identification of a 7-microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection. PubMed 31856390
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion